Russia's Health Ministry removes 23 medicinal products from registration

Russia's Health Ministry has cancelled registration certificates for 23 medicinal products, meaning they can no longer be manufactured, imported, or sold in the country. The drugs will disappear from pharmacies gradually as existing warehouse stocks are depleted.

The affected list spans both high-cost imported treatments for complex conditions and basic domestic products. Among the withdrawn brands are Kaletra for HIV, Remicade for arthritis and Crohn's disease, Sprycel and Temodal for oncology, and Cosmofer for anemia, alongside valerian with wormwood tincture, Gevkamen ointment, and vaseline oil from various manufacturers.

The ministry cited two drivers for the cleanup. Pharmaceutical companies often find it uneconomical to maintain licensing fees and re-registration for brands that have lost profitability due to newer therapies or cheaper generics. Simultaneously, regulators are removing redundant duplicates when a single active ingredient is already represented by multiple safe alternatives.

For patients, the measure carries no interruption risk, according to the ministry and industry experts. Every withdrawn product has bioequivalent replacements — copies with the same action — so therapy continues with only the packaging name changing. For example, doctors will prescribe lopinavir/ritonavir combinations from other manufacturers instead of Kaletra; the same principle applies to the oncology agents, whose patents have long expired and whose markets are filled with quality substitutes.

"None of the excluded drugs is unique or irreplaceable," industry experts note. The action reflects a planned regulatory consolidation, not a safety withdrawal.

Important: This article is for general information and does not replace medical advice. Do not start, stop, or change treatment without a qualified clinician.

Source: This article was adapted from an original Russian-language publication by Pravda.Ru.